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Abstract
Introduction: Visfatin, protein secreted by visceral adipose tissue, exerts insulin-mimetic actions. Visfatin concentration increases in 
patients with longer-standing diabetes type 2 with progressive b-cell dysfunction. Data about the role of visfatin in newly diagnosed 
glucose metabolism abnormalities are limited.
Evaluation of visfatin concentration in patients with obesity, in relation to the presence of newly diagnosed glucose metabolism disorders.
Material and methods: The study included 68 subjects with obesity, without a previous diagnosis of abnormal glucose metabolism. In all 
subjects we performed an oral glucose tolerance test, and according to the results the group was divided into the subgroups: A (n = 31), 
with glucose metabolism disorders (impaired fasting glucose, impaired glucose tolerance and type 2 diabetes); and B (n = 37), without 
abnormalities. In all subjects serum lipids, uric acid, C-peptide, glycated haemoglobin (HbA1c), creatinine, and serum visfatin concentra-
tions were measured. The control group comprised 30 lean, healthy individuals with normal glucose tolerance.
Results: We found elevated visfatin levels in obese individuals versus the control group (50.0 ± 48 vs. 26.7 ± 22.1 ng/mL; p = 0.01). Vis-
fatin concentrations in both subgroups, A and B, did not differ (40.86 ± 27.84 vs. 57.7 ± 59.79 ng/mL; p = 0.19). In subgroup A visfatin 
concentration correlated significantly with triglycerides (r = 0.37, p = 0.038), HbA1c (r = –0.43, p = 0.02), C-peptide (r = –0.38,p = 0.048), 
and waist-hip ratio (r = –0.41, p = 0.036).
Conclusions: The presence of newly diagnosed glucose metabolism abnormalities in obese subjects had no influence on the visfatin level, 
probably due to preserved endogenous insulin secretion and relatively short exposure to hyperglycaemia in patients with prediabetes or 
at early stage of type 2 diabetes. (Endokrynol Pol 2015; 66 (2): 108–113)
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Streszczenie
Wstęp: Wisfatyna, białko wydzielane przez trzewną tkankę tłuszczową, wykazuje działanie insulinomimetyczne polegające między 
innymi na zwiększeniu wychwytu glukozy przez komórki insulinowrażliwe. Stężenie wisfatyny wzrasta u osób z przewlekłą cukrzycą 
typu 2 wraz z postępującą dysfunkcją komórki b trzustki. Dane na temat roli wisfatyny w przypadku świeżo rozpoznanych zaburzeń 
gospodarki węglowodanowej są ograniczone.
Celem pracy była ocena stężenia wisfatyny u chorych z otyłością prostą w zależności od współistnienia świeżo rozpoznanych zaburzeń 
gospodarki węglowodanowej.
Materiał i metody: Przebadano 68 osób z otyłością prostą, bez rozpoznanych wcześniej zaburzeń gospodarki węglowodanowej. 
U wszystkich wykonano doustny test obciążenia glukozą, na podstawie którego wyodrębniono podgrupę A (n = 31) — z zaburzeniami 
gospodarki węglowodanowej (nieprawidłową glikemią na czczo, upośledzoną tolerancją glukozy i cukrzycą typu 2) oraz podgrupę B 
(n = 37) — bez zaburzeń. U wszystkich oznaczono stężenie cholesterolu całkowitego, HDL, LDL, triglicerydów, kwasu moczowego, 
peptydu-C, kreatyniny i wisfatyny. Grupę kontrolną stanowiło 30 szczupłych ochotników bez zaburzeń gospodarki węglowodanowej.
Wyniki: Stężenie wisfatyny u osób otyłych było istotnie wyższe w porównaniu z grupą kontrolną (50.0 ± 48 vs. 26.7 ± 22.1 ng/mL; p = 0.01). 
Stężenie wisfatyny w obu podgrupach, A i B, nie różniło się (odpowiednio 40.86 ± 27.84 vs. 57.7 ± 59.79 ng/mL; p = 0.19). W podgrupie A 
stężenie wisfatyny korelowało istotnie ze stężeniem triglicerydów (r = 0.37, p = 0.038), HbA1c (r = –0.43, p = 0.02), peptydem-C (r = –0.38, 
p = 0.048) i wskaźnikiem talia-biodra (r = –0.41, p = 0.036).
Wnioski: Obecność świeżo rozpoznanych zaburzeń gospodarki węglowodanowej u osób otyłych nie wpływała na stężenie wisfatyny, 
prawdopodobnie ze względu na zachowane endogenne wydzielanie insuliny i stosunkowo krótki okres narażenia na hiperglikemię 
u osób ze stanem przedcukrzycowym i świeżo wykrytą cukrzycą typu 2. (Endokrynol Pol 2015; 66 (2): 108–113)
Słowa kluczowe: wisfatyna; otyłość; cukrzyca; stan przedcukrzycowy
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Introduction
In 2005 visfatin mRNA was identified from visceral 
adipose tissue [1]. This protein had been previously 
known as a pre-B-cell colony-enhancing factor, act-
ing on lymphocyte maturation and inflammatory 
regulation [2]. It was also recognised as nicotinamide 
phosphoribosyltransferase (Nampt), the limiting en-
zyme in nicotinamide adenine dinucleotide (NAD) 
biosynthesis [3].
Increased circulating visfatin levels in obese subjects 
were confirmed in clinical studies [4–6].
In original work by Fukuhara et al. insulin-mimetic 
properties of visfatin were shown. This adipocytokine, 
by binding to the insulin receptor at a site distinct 
from insulin, increases glucose uptake in muscles and 
adipose tissue and inhibits hepatic gluconeogenesis 
[1]. Although the insulin-mimetic effect of visfatin was 
questioned, resulting in retraction of the article by 
an author in 2007 [7], numerous subsequent studies 
focused on the interaction between visfatin, insulin 
secretion, insulin resistance, and glucose homeostasis 
were published [6].
Recent studies suggest that visfatin may also act 
as a proinflammatory cytokine and in this way may 
indirectly participate in the development of insulin 
resistance and type 2 diabetes [8].
Visfatin has been widely studied as a potential factor 
linking obesity and diabetes type 2. Although results 
of these studies are often conflicting, there is evidence 
that visfatin concentration increases with progressive 
b-cell dysfunction in patients with longer-standing 
diabetes type 2 [6]. Data about visfatin concentration 
in newly diagnosed glucose metabolism abnormalities 
are limited.
The aim of our study was to evaluate visfatin 
concentrations in patients with obesity, in relation to 
the presence of newly diagnosed glucose metabolism 
abnormalities, and to find the relationship between 
visfatin and anthropometric and metabolic parameters 
in patients with and without glucose metabolism ab-
normalities.
Material and methods
This is a sub-analysis of the results of an already pub-
lished study [9], performed on a group of 68 obese 
patients — 53 females and 15 males (age 37.8 ± 13.2 
years, body mass index (BMI) 39.4 ± 6.4 kg/m2) without 
previous diagnosis of abnormal glucose metabolism. 
The control group consisted of 30 healthy, lean indi-
viduals - 24 females and 6 males (age 38.2 ± 14.9 years, 
BMI 22.8 ± 3.0 kg/m2), with normal glucose tolerance.
In the examined and control subjects, body weight, 
height, and waist and hip circumference were meas-
ured, then body mass index (BMI) and waist-hip ratio 
(WHR) were calculated. Oral glucose tolerance test 
(OGTT) was performed.
Examined individuals were divided, according 
to the results of OGTT, into subjects with glucose 
tolerance abnormalities (group A) and subjects with 
normal glucose tolerance (group B). Impaired glucose 
tolerance (IGT), impaired fasting glucose (IFG), and 
diabetes mellitus (DM) were defined according to 
WHO criteria [10]. Figure 1 shows the distribution of 
different glucose metabolism abnormalities in group 
A. All patients with glucose metabolism disorders were 
treatment-naïve. Characteristics of groups A and B are 
shown in Table I.
In both groups, A and B, total cholesterol, low den-
sity lipoprotein cholesterol (LDL-cholesterol), high den-
sity cholesterol (HDL-cholesterol), triglycerides (TG), 
uric acid, C-peptide, glycated haemoglobin (HbA1c), 
creatinine, and thyroid stimulating hormone (TSH) 
were estimated. Mean values of examined parameters 
in both groups are shown in Table II.
Serum visfatin concentration was assessed in 
groups A and B and in control subjects by ELISA 
method (Visfatin C-terminal [Human], Phoenix Phar-
maceuticals).
Figure 1. The distribution of different glucose metabolism 
disorders in group A (n = 31)
(DM — diabetes mellitus, IFG — impaired fasting glucose, IGT 
— impaired glucose tolerance)
Rycina 1. Rozpowszechnienie różnych zaburzeń gospodarki 
węglowodanowej w grupie A (n = 31) (DM — cukrzyca, IFG 
— nieprawidłowa glikemia na czczo, IGT — nieprawidłowa 
tolerancja glukozy)
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All subject participating in the study signed an 
informed consent form. The study was approved by 
the Bioethics Committee of the Ludwik Rydygier Col-
legium Medicum in Bydgoszcz, Nicolaus Copernicus 
University.
Statistical analysis
Statistical analysis of the results was performed. Results 
are presented as mean ± standard deviation (SD). We 
used the Shapiro-Wilk test to assess the normality of 
the distribution of the study variables. In the case of 
samples characterised by a normal distribution, the 
means were compared with the use of Student’s t-test 
for independent variables. Where the distribution 
significantly differed from the normal distribution, 
the significance of between-group comparisons was 
verified using the non-parametric Mann-Whitney U 
test. The relationship between two variables was as-
sessed with Pearson’s linear correlation coefficient (r). 
A p value of less than 0.05 was considered statistically 
significant. All the calculations were performed using 
the Statistica software.
Results
Serum visfatin concentration was significantly higher in 
obese subjects than in the control group (50.0 ± 48 vs. 26.7 ± 
± 22.1 ng/mL; p = 0.01). No difference in visfatin con-
centration between groups A and B was found (40.86 ± 
± 27.84 vs. 57.7 ± 59.79 ng/mL; p = 0.19).
In group A with glucose tolerance abnormalities, 
visfatin concentration correlated significantly with TG 
(r = 0.37, p = 0.038), C-peptide (r = –0.49, p = 0.009), 
HbA1c (r = –0.43, p = 0.02) and WHR (r = –0.41, p = 0.036). 
In group B and in the control group, visfatin did not 
correlate with any anthropometric or biochemical pa-
rameters. Figures 2, 3, and 4 show correlations in group 
A between visfatin and C-peptide, visfatin and HbA1c, 
visfatin and WHR, respectively.
Discussion
The pathogenic relationship between obesity and dia-
betes exists. Obese or overweight subjects are at higher 
risk for development of type 2 diabetes [11]. Abdominal 
fat accumulation is associated with insulin resistance 
and is an independent risk factor for developing dia-
betes. Visceral fat is a source of free fatty acids (FFA). 
Elevated FFA and their conversion to long chain acyl 
Table I. The characteristics of group A (with glucose meta-
bolism disorders) and group B (with normal glucose tolerance)
Tabela I. Charakterystyka grupy A (z zaburzeniami gospo-
darki węglowodanowej) i grupy B (z prawidłową tolerancją 
glukozy)
Parameter (unit) Group A Group B p
Mean ± SD Mean ± SD
Age [years] 41.3 ± 14.1 33.6 ± 10.7 < 0.05
BMI [kg/m2] 40.8 ± 6.9 37.3 ± 4.5 < 0.05
Waist circumference  
[cm]
121.11 ± 15.9 110.4 ± 10.8 < 0.05
Hip circumference  
[cm]
129.6 ± 14.3 123 ± 11 < 0.05
WHR 0.94 ± 0.1 0.9 ± 0.1 0.27 (NS)
SD — standard deviation; BMI — body mass index; WHR — waist to hip ratio
Table II. Mean values of examined parameters in group A (with glucose metabolism disorders) and B (with normal glucose 
tolerance)
Tabela II. Średnie wartości badanych parametrów w grupie A (z zaburzeniami gospodarki węglowodanowej) i grupie B 
(z prawidłową tolerancją glukozy)
Parameter (unit) Group A Group B p
Mean ± SD Mean ± SD
Fasting glucose [mg/dL] 106.1 ± 14.0 87.6 ± 6.3 < 0.00001
2-hour glucose (OGTT) [mg/dL] 158.7 ± 40.5 103.2 ± 19.9 < 0.00001
HbA1c (%) 6.05 ± 0.8 5.4 ± 0.28 < 0.001
C-peptide [ng/dL] 3.52 ± 2.13 2.59 ± 1.8 < 0.001
Total cholesterol [mg/dL] 190.8 ± 25.14 187.9 ± 32.9 0.69 (NS)
LDL cholesterol [mg/dL] 115.3 ± 21.17 112.9 ± 30.5 0.71 (NS)
HDL cholesterol [mg/dL] 45.4 ± 7.16 48.7 ± 8.9 0.09 (NS)
Triglycerides [mg/dL] 152.5 ± 70.8 129.9 ± 61.7 < 0.05
Uric acid [mg/dL] 5.69 ± 1.51 4.77 ± 1.5 < 0.05
TSH [μIU/mL] 1.91 ± 1.43 1.92 ± 1.28 0.98 (NS)
SD — standard deviation; OGTT — oral glucose tolerance test; HbA1c — glycated haemoglobin; TSH — thyroid stimulating hormone
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Figure 4. Correlation between visfatin and WHR in group A. 
WHR — waist to hip ratio; r — Pearson’s linear correlation 
coefficient
Rycina 4. Korelacja pomiędzy wisfatyną a WHR w grupie A. 
WHR — wskaźnik talia–biodra; r – współczynnik korelacji 
Pearsona
Figure 2. Correlation between visfatin and C-peptide in group A. 
r — Pearson’s linear correlation coefficient
Rycina 2. Korelacja pomiędzy wisfatyną a peptydem-C w grupie 
A. r — współczynnik korelacji Pearsona
Figure 3. Correlation between visfatin and HbA1c in group A. 
HbA1c — glycated haemoglobin; r — Pearson’s linear correlation 
coefficient
Rycina 3. Korelacja pomiędzy wisfatyną a HbA1c w grupie A. 
HbA1c — hemoglobina glikowana; r — współczynnik korelacji 
Pearsona
CoA derivatives result in reduced insulin signalling 
and glucose transport. “Lipotoxicity” and the resulting 
oxidative stress may contribute to the decline in b-cell 
mass and diminished insulin secretion [12]. Obesity-
associated changes in circulating adipocytokines may 
contribute to both B-cell destruction and increased 
insulin resistance [12,13]. Visfatin, an adipocytokine 
with insulin-mimetic activity [1] and proinflammatory 
actions [8], is considered as a potential factor that may 
contribute to the development of diabetes in obese 
individuals.
The mechanisms of visfatin secretion and action 
are not fully understood. Haider at al. showed that 
visfatin is upregulated in a glucose-dependent manner. 
Hyperglycaemia induced an increase in visfatin concen-
tration, and the release of visfatin was dependent on 
the duration and the magnitude of glucose elevation. 
Glucose-induced increase of visfatin was prevented by 
hyperinsulinaemia [14]. Recently, Kowalska et al. found 
decreased visfatin levels after insulin infusion and an 
increase of visfatin after FFA infusion that induced 
insulin resistance [15]. Thus, the increase of visfatin, 
observed in patients with type 2 diabetes, may be 
a result of b-cell dysfunction [16] or insulin inability to 
suppress visfatin production in insulin-resistant condi-
tions [15]. On the other hand, a recent experimental 
study by Cheng demonstrates that visfatin protects 
pancreatic b-cells from FFA-induced apoptosis, via the 
mitogen-activated protein kinase/phosphoinositide 
3-kinase pathway. One might suggest that the increase 
of visfatin seen in obesity and obesity-associated dis-
eases may be a compensatory mechanism of the body 
to protect b-cells against metabolic dysfunction induced 
by cellular exposure to FFAs [17].
We found higher plasma visfatin levels in obese 
subjects than in lean individuals, but no difference 
in visfatin concentration was found between two 
subgroups of obese patients: with impaired glucose 
metabolism and with normal glucose tolerance. In the 
subgroup with glucose metabolism disorders visfatin 
correlated significantly negatively with C-peptide, 
HbA1c and WHR and positively with triglycerides con-
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centration. In contrast, in the subgroup with normal 
glucose tolerance visfatin did not correlate with any of 
examined parameters.
Most of our patients with glucose metabolism ab-
normalities had prediabetes — IFG, IGT, or both. The 
lack of difference in visfatin concentration between two 
subgroups is consistent with the findings obtained by 
other authors who evaluated visfatin levels in individu-
als with prediabetes [18–20]. Dogru found no difference 
in the plasma levels of visfatin between non-obese 
patients with newly diagnosed diabetes and newly di-
agnosed impaired glucose tolerance, as well as between 
patients with impaired glucose tolerance and healthy 
controls. In this study visfatin levels were higher in the 
diabetic group than in controls [20]. Elevated visfatin 
concentration in patients with type 2 diabetes was 
shown by other authors [16, 21–24]. In patients with 
longer-standing diabetes type 2 and with endogenous 
insulin deficiency (more than one third of patients were 
treated with insulin), visfatin concentration increased 
with progression of b-cell dysfunction and with wors-
ening of glycaemia control [16]. In our study, patients 
with glucose metabolism abnormalities had higher 
C-peptide levels than did subjects with normal glucose 
tolerance. This may reflect a compensatory (to probable 
insulin resistance) increase of insulin secretion and 
confirms preserved b-cell function in our patients with 
prediabetes or at early stage of type 2 diabetes.
Similarly to the Lopez-Bermejo study [16], in our pa-
tients visfatin concentration increased with decreased 
endogenous insulin secretion. However, in contrast to 
the above-mentioned study, in our group of patients 
visfatin declined with increasing HbA1c. This is con-
sistent with the results presented by Li et al. [25]. We 
can suppose that in our subjects insulin secretion was 
sufficient to inhibit visfatin release, and glucose levels 
were too low (mean HbA1c level 6.05 ± 0.8%) to stimu-
late visfatin increase. This may also explain the lack of 
differences in visfatin concentration between the two 
study subgroups.
Positive correlation of visfatin and triglycerides, 
found in our patients with impaired glucose metabo-
lism, was also shown in patients with newly diagnosed 
type 2 diabetes [24] in obese women with metabolic 
syndrome [26] and in healthy young men [27]. Hyper-
triglyceridemia is typical for individuals with visceral 
obesity and insulin resistance. When insulin resistance 
develops, increased lipolysis results in FFA elevation 
and excessive production of glucose and triglycerides 
[28]. The correlation between visfatin and insulin resist-
ance was shown in a meta-analysis by Chang et al. [6]. 
We did not evaluate insulin resistance and thus, on the 
basis of our data, it is not possible to explain the causal 
relationship between visfatin and triglycerides.
It was demonstrated by Fukuhara that plasma 
visfatin levels strongly correlate with the quantity of 
visceral adipose tissue assessed by computed tomog-
raphy [1]. Although conflicting results were obtained 
in different studies assessing correlations between 
visfatin and anthropometric parameters [16, 19, 29], 
there is evidence that plasma visfatin levels are largely 
determined by body weight, probably mainly by vis-
ceral adipose tissue [6]. A significant decrease in mean 
serum visfatin concentration was found in girls with 
anorexia nervosa, the disease that leads to significant 
reduction of adipose tissue mass [30].
The lack of correlation between visfatin and BMI 
or waist circumference found in our patients was also 
confirmed by other authors in patients with diabetes 
[16], in obese non-diabetic patients [29] and in non-
obese patients with newly diagnosed type 2 diabetes 
and impaired glucose tolerance [20]. We found nega-
tive correlation between visfatin and WHR in obese 
subjects with glucose metabolism disorders. Our results 
could suggest that higher visfatin levels are associated 
with the adipose tissue distribution pattern typical for 
gynoid rather than visceral obesity. It should, however, 
be taken into account that measuring waist circumfer-
ence does not reliably distinguish a large waist due to 
subcutaneous tissue versus visceral fat [28].
Conclusions
Obese subjects had higher visfatin levels in comparison 
with lean individuals. The presence of newly diagnosed 
glucose metabolism abnormalities in obese subjects 
had no influence on the visfatin level, probably due to 
preserved endogenous insulin secretion and short ex-
posure to hyperglycaemia in patients with prediabetes 
or at early stage of type 2 diabetes.
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